🏠 Home How to use e-mentor 🎁 Earn Gifts by Studying
📚 Study Hub
🤖 AI Study PlannerPAID 🔁 Recap Cards ⚔️ 1v1 Study Duels NEW 📋 Test Series 💎 Test Series PackagesTIERS 🎁 Invite FriendsFREE PLANNER 📖 Track Chapters
⚡ Focus & Tools
🎧 Virtual Focus Room LIVE ⏱ Pomodoro Timer 🏆 Leaderboard 🎁 Earn Gifts by Studying
🌐 Community & Info
✍️ Blog ❓ Frequently Asked Questions ℹ️ Read Me First
Login Join Free
📢 UPDATES
📅 25th All India Debate Competition 2026  |  🏆 Leaderboard resets weekly — Keep your streak alive!  |  💡 Join Discussion Board for exam doubt clearing  |  📅 25th All India Debate Competition 2026  |  🏆 Leaderboard resets weekly — Keep your streak alive!  |  💡 Join Discussion Board for exam doubt clearing  | 

Ch 1: BASICS OF CAPITAL MARKET — V2: Practical Scenarios & Case Laws

CS Executive 📚 Capital Market & Securities Laws 📖 Ch.1 — BASICS OF CAPITAL MARKET 📘 V2: Study Material & Test Yourself ⚡ Free Mode (Answers Locked)
⏱ Duration: 90 Mins 🎯 Total Marks: 50 Passed at: 20 Marks Max Attempts: 10
⚖️ Statutory Applicability: Applicable for ICSI CS Executive Examinations (December 2026 Attempt - Syllabus 2022)

Exhaustive ICSI CS Executive Test Series with 4-Tier Rubrics, Statutory Analysis, and Real-world Corporate Problem Scenarios.

Login to Enroll & Start Join Free

📑 Exam Questions

5 Questions • Total 50 Marks

Question 1: Structure of Indian Capital Market: Primary market vs Secondary market roles.

10 Marks
📌 Applicable SEBI ICDR (Third Amendment) Regulations and streamlined T+3 listing timeline mandates.
M/s Horizon Agro-Tech Limited proposes to raise capital through an Initial Public Offering (IPO) while concurrently dealing with liquidity and secondary market stability concerns for its existing unlisted shares trading on unregulated platforms. M/s Sahyadri Capital Advisors, acting as Merchant Bankers, approaches your firm for a comprehensive 4-Tier Legal Opinion regarding the regulatory interplay between the Primary and Secondary markets under the SEBI Act, 1992, the Securities Contracts (Regulation) Act, 1956 (SCRA), and the SEBI (ICDR) Regulations, 2018. Advise Horizon Agro-Tech Limited on the statutory compliance frameworks, disclosure timelines, pricing mechanics, and penal consequences under Sections 15A to 15HB of the SEBI Act, 1992, for any primary-secondary market anomalies.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)

Question 2: Capital market instruments: Equity shares, preference shares, debentures, FCCBs, IDRs.

10 Marks
📌 Applicable SEBI (ICDR) Regulations, 2018, SEBI (SAST) Regulations, 2011, and FEMA Non-debt Instruments Rules, 2019.
Sahyadri Global Ltd., an Indian listed issuer, intends to raise capital through the issuance of Foreign Currency Convertible Bonds (FCCBs) amounting to USD 50 million and Indian Depository Receipts (IDRs) amounting to Rs 200 crore to fund its domestic expansion. Concurrently, an institutional investor holding 14% equity seeks to convert its optionally convertible debentures (OCDs) into equity shares, triggering potential creeping acquisition limits under SEBI (SAST) Regulations, 2011. As the Practising Company Secretary, formulate a 4-Tier Legal Opinion addressing the structuring, pricing guidelines under FEMA/RBI and SEBI (ICDR) Regulations, 2018, minimum public shareholding requirements under SEBI (LODR) Regulations, 2015, and penal implications for non-compliance under the SEBI Act, 1992.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)

Question 3: Types of institutional investors: Foreign Portfolio Investors (FPIs), Alternative Investment Funds (AIFs), Mutual Funds.

10 Marks
📌 Incorporates SEBI (SAST) (Amendment) Regulations, SEBI (PIT) (Amendment) Regulations, and latest SAT jurisprudence on institutional investor independence.
Sahyadri Pharma Ltd., a listed company, faces an investigation by SEBI concerning simultaneous investments made by Sahyadri Horizon FPI (a Category II Foreign Portfolio Investor), Kalinga Growth AIF (a Category III Alternative Investment Fund), and Meridian Mutual Fund. Sahyadri Horizon FPI holds 8.5% of the total paid-up equity share capital of Sahyadri Pharma Ltd. Kalinga Growth AIF, registered under SEBI (Alternative Investment Funds) Regulations, 2012, has accumulated a 6.2% equity stake. Meridian Mutual Fund holds a 5.8% equity stake across its various schemes. Recently, Sahyadri Pharma Ltd. announced a preferential issue of equity shares and convertible warrants to a promoter group entity. Following this announcement, complaints were lodged alleging that Sahyadri Horizon FPI, Kalinga Growth AIF, and Meridian Mutual Fund are acting in concert (PAC) with the promoters under Regulation 2(1)(q) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (SAST Regulations, 2011), and that their combined holding of 20.5% triggers mandatory open offer requirements under Regulation 3(1) and 3(2) of the SAST Regulations, 2011. Furthermore, SEBI has alleged that certain key executives of Kalinga Growth AIF traded in the securities of Sahyadri Pharma Ltd. prior to the announcement of the preferential issue, based on unpublished price-sensitive information (UPSI) shared during a due diligence exercise, thereby violating Regulation 3 and 4 of SEBI (Prohibition of Insider Trading) Regulations, 2015 (PIT Regulations, 2015). As a Company Secretary and Senior Legal Consultant, draft a comprehensive 4-Tier Legal Opinion addressing: (i) The applicability of PAC status and open offer obligations for the institutional investors under the SAST Regulations, 2011, factoring in statutory exemptions; (ii) The legal validity of the insider trading allegations against Kalinga Growth AIF under the PIT Regulations, 2015, and relevant SAT precedents; (iii) The disclosure obligations under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR Regulations, 2015) and SEBI (FPI) Regulations, 2019; and (iv) The penal consequences under Sections 15A, 15G, and 15HB of the SEBI Act, 1992, along with a structured Secretarial Action Plan.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)

Question 4: Comprehensive review of key exam provisions of BASICS OF CAPITAL MARKET (Part 4)

10 Marks
📌 Incorporates latest SEBI PIT (Amendment) Regulations regarding SDD maintenance and Supreme Court precedents on circumstantial evidence in insider trading.
AstraZeneca Lifesciences Ltd., a listed entity on the Main Board of BSE and NSE, witnessed unusual trading volumes and a sudden 18% spike in its share price two days prior to the formal board announcement regarding a proposed demerger of its specialized research division into a newly incorporated wholly-owned subsidiary, 'AstraZeneca Research India Ltd.'. SEBI initiated a preliminary investigation and discovered that Mr. Vikramaditya, the Chief Strategy Officer, had communicated unpublished price-sensitive information (UPSI) regarding the restructuring to his close relative, Ms. Shreya, who subsequently acquired 1,50,000 shares through multiple broker accounts before the announcement. Simultaneously, foreign portfolio investor 'Horizon Global Alpha Fund' breached the 15% shareholding threshold in AstraZeneca Lifesciences Ltd. without making necessary disclosures under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. As the Senior Practicing Company Secretary appointed to advise the Audit Committee and Board of Directors of AstraZeneca Lifesciences Ltd., formulate an exhaustive 4-Tier Legal Opinion addressing the insider trading liabilities, UPSI compliance failures, disclosure breaches under SAST Regulations, applicable penal provisions under the SEBI Act, 1992, and the mandatory Secretarial Action Plan.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)

Question 5: Comprehensive review of key exam provisions of BASICS OF CAPITAL MARKET (Part 5)

10 Marks
📌 Incorporates updated SEBI SAST, PIT, and LODR compliance standards regarding SDD and FPI disclosures.
Sahyadri Growth Fund (Mauritius) Ltd., a Foreign Portfolio Investor (FPI) registered under SEBI (FPI) Regulations, 2019, holds a 12.5% equity stake in Kalinga Pharmaceuticals Ltd., a listed company on NSE and BSE. On 10th October 2023, Sahyadri acquired an additional 4.2% equity stake through an off-market block deal, breaching total shareholding beyond 15% and crossing the 5% incremental threshold in a financial year without prior public disclosures or open offer considerations under SEBI (SAST) Regulations, 2011. Concurrently, SEBI's automated surveillance system flagged unusual trading volumes and price spikes in Kalinga shares prior to the block deal announcement, indicating potential leakage of Unpublished Price Sensitive Information (UPSI) under SEBI (PIT) Regulations, 2015. Kalinga Pharmaceuticals Ltd. failed to maintain its Structured Digital Database (SDD) adequately, and key managerial personnel traded during the trading window closure. The Board of Directors of Kalinga seeks a comprehensive 4-Tier Legal Opinion from a Company Secretary-cum-Securities Law Expert detailing the compounding liability, open offer triggers, regulatory filings, and Secretarial Action Plan.
🔒 Official Model Solution
Model answers and self-evaluation solutions are available in the Premium Tier & Rankers Plan.
Unlock Answers (₹1,000)
Advertisement

Quick Pomodoro Timer

Select a focus duration to launch your session:

25m Standard 50m Deep Focus 15m Quick Sprint
🎧 Join Virtual Focus Room (with 40Hz Audio) →
🔔
Daily Study Reminders
Get notified 15m before your target study sessions.